These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30084688)

  • 1. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
    Tirosh A; Nilubol N; Patel D; Kebebew E
    Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Utility of Total
    Tirosh A; Papadakis GZ; Millo C; Hammoud D; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
    Gastroenterology; 2018 Mar; 154(4):998-1008.e1. PubMed ID: 29155309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total
    Tirosh A; Papadakis GZ; Millo C; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
    Eur J Endocrinol; 2017 May; 176(5):575-582. PubMed ID: 28289088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
    Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
    Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
    Padelli M; Bruno C; Lemarchand J; Vourc'h P; Andres C; Blasco H; Benz-de Bretagne I
    Ann Biol Clin (Paris); 2019 Apr; 77(2):161-168. PubMed ID: 30998196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
    Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
    Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
    Gut P; Ruchała M
    Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours.
    Ohlsson H; Spaak E; Gålne A; Sundlöv A; Almquist M
    J Neuroendocrinol; 2024 Aug; 36(8):e13396. PubMed ID: 38679928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
    Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
    Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
    Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
    BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications.
    Merola E; Pavel ME; Panzuto F; Capurso G; Cicchese N; Rinke A; Gress TM; Iannicelli E; Prosperi D; Pizzichini P; Prasad V; Kump P; Lipp R; Partelli S; Falconi M; Wiedenmann B; Delle Fave G
    J Clin Endocrinol Metab; 2017 May; 102(5):1486-1494. PubMed ID: 28324047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
    Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
    Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Usefulness of
    Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
    Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.